MA53643A - Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 - Google Patents

Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6

Info

Publication number
MA53643A
MA53643A MA053643A MA53643A MA53643A MA 53643 A MA53643 A MA 53643A MA 053643 A MA053643 A MA 053643A MA 53643 A MA53643 A MA 53643A MA 53643 A MA53643 A MA 53643A
Authority
MA
Morocco
Prior art keywords
dioxocyclobutenylamino
picolinamide
hydroxy
substituted
useful
Prior art date
Application number
MA053643A
Other languages
English (en)
Inventor
Andrew Christopher Flick
Brian Stephen Gerstenberger
Daniel Wei-Shung Kung
Vincent Michael Lombardo
James John Mousseau
Philippe Marcel Nuhant
Jr Ralph Pelton Robinson
Daniel Copley Schmitt
Mark Edward Schnute
Atli Thorarensen
John Isidro Trujillo
Rayomand Jal Unwalla
Huixian Wu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA53643A publication Critical patent/MA53643A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MA053643A 2018-09-21 2019-09-18 Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 MA53643A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862734486P 2018-09-21 2018-09-21

Publications (1)

Publication Number Publication Date
MA53643A true MA53643A (fr) 2021-12-29

Family

ID=68051869

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053643A MA53643A (fr) 2018-09-21 2019-09-18 Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6

Country Status (30)

Country Link
US (2) US10975065B2 (fr)
EP (1) EP3852879A1 (fr)
JP (1) JP6989729B2 (fr)
KR (2) KR102615234B1 (fr)
CN (2) CN112672791B (fr)
AR (1) AR116464A1 (fr)
AU (1) AU2019344107B2 (fr)
BR (1) BR112021003956A2 (fr)
CA (1) CA3055805A1 (fr)
CL (1) CL2021000683A1 (fr)
CO (1) CO2021003391A2 (fr)
CR (1) CR20210146A (fr)
CU (1) CU20210016A7 (fr)
DO (1) DOP2021000045A (fr)
EA (1) EA202190586A1 (fr)
EC (1) ECSP21018584A (fr)
GE (1) GEP20237476B (fr)
IL (1) IL281634B1 (fr)
MA (1) MA53643A (fr)
MX (1) MX2021003318A (fr)
NI (1) NI202100012A (fr)
NZ (1) NZ773473A (fr)
PE (1) PE20211070A1 (fr)
PH (1) PH12021550554A1 (fr)
SG (1) SG11202101827RA (fr)
TW (1) TWI754172B (fr)
UA (1) UA128700C2 (fr)
UY (1) UY38379A (fr)
WO (1) WO2020058869A1 (fr)
ZA (1) ZA202101169B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20237476B (en) * 2018-09-21 2023-03-27 Pfizer N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
WO2021219849A1 (fr) 2020-04-30 2021-11-04 Idorsia Pharmaceuticals Ltd Dérivés d'azétidin-3-ylméthanol en tant que modulateurs du récepteur ccr6
WO2023057548A1 (fr) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur ccr6
CN118215662A (zh) 2021-10-26 2024-06-18 爱杜西亚药品有限公司 Ccr6受体调节剂
IL312369A (en) 2021-10-28 2024-06-01 Idorsia Pharmaceuticals Ltd CCR6 receptor modulators
CN116162081B (zh) * 2022-12-13 2024-08-09 药康众拓(江苏)医药科技有限公司 一类氘代吡啶酰胺类ccr6抑制剂药物及用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354763A (en) 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
HU218794B (hu) 1994-11-16 2000-12-28 American Home Products Corporation Diamino-ciklobutén-3,4-dionok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
EP0901786B1 (fr) 1997-08-11 2007-06-13 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
US6495576B2 (en) 2001-02-07 2002-12-17 Abbott Laboratories Aminal diones as potassium channel openers
CZ20032831A3 (cs) 2001-04-16 2004-03-17 Schering Corporation 3,4-Disubstituované cyklobuten-1,2-diony
NZ535314A (en) 2002-03-18 2007-08-31 Schering Corp Combination treatments for chemokine-mediated diseases
ATE422203T1 (de) * 2002-10-09 2009-02-15 Schering Corp Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden
CN101203509B (zh) 2005-02-16 2013-05-08 默沙东公司 具有cxcr3拮抗剂活性的胺-连接的吡啶基和苯基取代的哌嗪-哌啶
CA2648033A1 (fr) 2006-03-31 2007-10-11 Janssen Pharmaceutica N.V. Derives de 3,4-diamino-3-cyclobutene-1,2-dione en tant qu'agents d'ouverture du canal potassique
JP5437061B2 (ja) 2006-05-26 2014-03-12 アッヴィ・インコーポレイテッド ポロ様キナーゼの阻害薬
RU2009103999A (ru) 2006-07-07 2010-08-20 Шеринг Корпорейшн (US) 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокиновых рецепторов
NZ580660A (en) 2007-04-30 2012-02-24 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
EP2155670B1 (fr) 2007-06-06 2012-04-18 Novartis AG Composés de cyclobutènedione substitués anti-inflammatoires
US20100249439A1 (en) 2007-07-05 2010-09-30 Vincenzo Liotta Process for controlled crystal size in 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
WO2009012375A2 (fr) 2007-07-19 2009-01-22 Wyeth Inhibiteurs de la squarate kinase
EP2173713B1 (fr) 2007-07-24 2016-02-17 Bristol-Myers Squibb Company Dérivés acycliques en tant que modulateurs de l'activité du récepteur de la chimiokine
WO2009015166A1 (fr) 2007-07-24 2009-01-29 Bristol-Myers Squibb Company Dérivés de pipéridine en tant que modulateurs d'activité de récepteur de chimiokine
US20110009482A1 (en) 2007-12-04 2011-01-13 Schering Corporation Methods of treating copd
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (fr) 2008-12-05 2010-06-10 Novartis Ag Cyclobutène-1,2-diones 3,4-disubstituées en tant qu'antagonistes de récepteur cxcr2
WO2010131146A1 (fr) 2009-05-12 2010-11-18 Pfizer Limited Dérivés de cyclobutène-dione
PL2473049T3 (pl) 2009-09-04 2019-07-31 Biogen Ma Inc. Inhibitory kinazy tyrozynowej brutona
CN102711766B (zh) 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-取代的嘌呤化合物、组合物和使用方法
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
CA2873984A1 (fr) 2012-05-23 2013-11-28 Stemergie Biotechnology Sa Inhibiteurs de l'activite du complexe (iii) de la chaine de transport d'electrons mitochondriale et utilisation de ceux-ci
JP6363616B2 (ja) 2012-12-19 2018-07-25 ノバルティス アーゲー オートタキシン阻害剤
JP2016509602A (ja) 2013-01-25 2016-03-31 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎の処置のためのスクアリン酸誘導体
JP2016518316A (ja) 2013-03-15 2016-06-23 セルジーン アビロミクス リサーチ， インコーポレイテッド Ｍｋ２阻害剤およびそれらの使用
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
US10660909B2 (en) * 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
GEP20237476B (en) * 2018-09-21 2023-03-27 Pfizer N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors

Also Published As

Publication number Publication date
US11708360B2 (en) 2023-07-25
CU20210016A7 (es) 2021-10-12
CO2021003391A2 (es) 2021-04-08
UA128700C2 (uk) 2024-10-02
IL281634B1 (en) 2024-10-01
KR20230175326A (ko) 2023-12-29
KR102615234B1 (ko) 2023-12-19
EP3852879A1 (fr) 2021-07-28
ECSP21018584A (es) 2021-04-29
UY38379A (es) 2020-04-30
TWI754172B (zh) 2022-02-01
TW202024056A (zh) 2020-07-01
US20200095239A1 (en) 2020-03-26
AU2019344107A1 (en) 2021-04-08
BR112021003956A2 (pt) 2021-05-25
MX2021003318A (es) 2021-05-14
GEP20237476B (en) 2023-03-27
PH12021550554A1 (en) 2022-02-21
CL2021000683A1 (es) 2021-10-15
CR20210146A (es) 2021-05-20
IL281634A (en) 2021-05-31
JP6989729B2 (ja) 2022-01-05
DOP2021000045A (es) 2021-04-30
CN116874466A (zh) 2023-10-13
WO2020058869A1 (fr) 2020-03-26
AU2019344107B2 (en) 2022-09-15
NI202100012A (es) 2021-06-22
NZ773473A (en) 2023-07-28
KR20210046717A (ko) 2021-04-28
PE20211070A1 (es) 2021-06-09
EA202190586A1 (ru) 2021-07-05
JP2021532166A (ja) 2021-11-25
AR116464A1 (es) 2021-05-12
US20210206757A1 (en) 2021-07-08
SG11202101827RA (en) 2021-04-29
ZA202101169B (en) 2022-07-27
CA3055805A1 (fr) 2020-03-21
CN112672791A (zh) 2021-04-16
US10975065B2 (en) 2021-04-13
CN112672791B (zh) 2023-10-03

Similar Documents

Publication Publication Date Title
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA49013A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA53643A (fr) Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA51616A (fr) Inhibiteurs d'adn-pk
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
MA51433A (fr) Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase